Immunotherapy has revolutionized cancer treatment, with ICIs including monoclonal anti‐PD‐1, anti‐PD‐L1, and anti‐CTLA‐4 having significantly improved survival outcomes in lung cancer and melanoma patients.16, 17, 18. The gene discussed is CTLA4; the disease is lung carcinoma.